First Turn Management’s Terns Pharmaceuticals TERN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-326,694
Closed -$17.2M – 37
2026
Q1
$17.2M Sell
326,694
-545,355
-63% -$22.4M 1.92% 26
2025
Q4
$35.2M Buy
+872,049
New +$20.2M 4.03% 10

Other funds holding TERN

First Turn Management's TERN Position: Q2 2026 in Review

First Turn Management sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 326,694 shares — an estimated $17.2M sold.

First Turn Management first reported a position in TERN in Q4 2025 and held it in 2 quarters. The position peaked at $35.2M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • First Turn Management reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • First Turn Management sold 326,694 Terns Pharmaceuticals shares in Q2 2026, an estimated $17.2M.
  • First Turn Management first reported a position in Terns Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • First Turn Management's Terns Pharmaceuticals position peaked at $35.2M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on First Turn Management's 13F filing for Q2 2026, filed 14 Aug 2026.